Showing 411-420 of 4927 results for "".
Multiplexed 1,440 and 1,320 nm Laser for Chronic Photodamage
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/multiplexed-1-440-and-1-320-nm-laser-for-chronic-photodamage/19352/Dr. Bernstein discusses the benefits of a multiplexed dual wavelength non-ablative laser for treatment of photodamage.On the Leading Edge, Not the Bleeding Edge: Joe Niamtu, DMD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/on-the-leading-edge-not-the-bleeding-edge-joe-niamtu-dmd/18606/Innovator, influencer, and podium perennial Joe Niatmu, III, DMD has built a successful surgical aesthetic practice by focusing on the basics, concentrating on his strengths, and avoiding passing fads. How does he stay passionate, spot the best new developments, and build a fulfilling practice? In t2024 Tips: The Latest in Hair and Nails
https://practicaldermatology.com/topics/hair-nails/2024-tips-latest-hair-and-nails/26949/2024 Tips: The Latest in Hair and NailsPanic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term Strategy
https://practicaldermatology.com/topics/practice-management/panic-induced-digital-marketing-avoid-short-sighted-shifts-in-long-term-strategy/26662/Panic-induced Digital Marketing: Avoid Short-sighted Shifts in Long-term StrategyDermWireTV: Epsolay Approval; See My Skin from Vaseline; Jori Launch; Novartis Grant for Farmworker Justice
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-epsolay-approval-see-my-skin-from-vaseline-jori-launch-novartis-grant-for-farmworker-justice/20094/Vaseline’s new See My Skin Campaign aims to help consumers of all skin types recognize skin diseases and connect them with dermatologists who can help manage them. Uchenna Okereke, MD discusses the initiative. Farmworker Justice, an organization dedicated to empowering farmworkers to improve immigraMichael Gold Honored, CSF Highlights, Anxiety Linked to Skin Disease
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-michael-gold-honored-csf-highlights-anxiety-linked-to-skin-disease/18720/From bloodless blephs to nutraceuticals, innovative approaches to patient care take the spotlight at Cosmetic Surgery Forum each year. This year, the meeting introduced new topics and new speakers, says CSF founder and Practical Dermatology Chief Cosmetic Surgery Editor, Dr. Joel Schlessinger. Dr. MDermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eDermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshDermWireTV: Cassiopeia Winlevi; Psoriasis Guidelines; Cyndi Lauper's PsO in the Know; Sarah Michelle Gellar's CoolSculpting
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cassiopeia-winlevi-psoriasis-guidelines-cyndi-laupers-pso-in-the-know-sarah-michelle-gellars-coolsculpting/19852/The FDA has approved Winlevi (Clascoterone cream 1%) from Cassiopea for the treatment of acne in patients 12 years and older.New Guidelines of care for the Management of Psoriasis with Systemic Nonbiologic Therapies, jointly issued by the American Academy of Dermatology and the National Psoriasis FoDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)